Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Yttrium Y 90 Resin Microspheres in Collecting Data from Patients with Liver Cancer That Cannot Be Removed by Surgery for the RESIN Liver Tumor Study

Liver

This research trial studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting SIR-spheres in non-resectable (RESIN) liver tumor study. The information generated will help doctors better understand treatment patterns involving Y90 therapy, gain additional insights in the long-term outcomes for patients, as well as guide future research for using Y90 therapy, especially for those conditions where data is currently very limited or lacking.
Liver
N/A
Brown, Daniel
NCT02685631
VICCGI1523

Suppression and Analysis of Ultrasonic Clutter During Liver Focal Lesion Biopsy

Liver

Liver
N/A
Byram, Brett
VICCGI15145

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Liver

This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1 in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) or FGFR2 gene mutations or amplifications (based on NGS testing performed or commissioned by the respective study center) and who received at least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at 300 mg of derazantinib capsules.
Liver
II
Goff, Laura
NCT03230318
VICCGI1754

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: